Research analysts who have asked questions during InflaRx earnings calls.
DG
Dae Gon Ha
Stifel
1 question for IFRX
Also covers: ABEO, BEAM, CRBP +10 more
DJ
Derek Johnson
Guggenheim Partners
1 question for IFRX
JT
Jennifer Teubl
Robert W. Baird & Co.
1 question for IFRX
ML
Matthew Luchini
BMO Capital Markets
1 question for IFRX
Also covers: BOLD
Tessa Romero
JPMorgan Chase & Co.
1 question for IFRX
Also covers: ACAD, AGIO, CYTK +5 more
Timur Ivannikov
Raymond James
1 question for IFRX
Also covers: APLS, GLMD, MIRM
Recent press releases and 8-K filings for IFRX.
InflaRx Provides Update on Vilobelimab Phase 3 Data Analyses
IFRX
New Projects/Investments
- InflaRx's Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint.
- Subsequent post-hoc analyses of the Phase 3 data, involving 54 patients, suggest a positive trend in favor of vilobelimab, with signals indicating a potentially consistent treatment effect.
- The company plans to meet with the U.S. Food and Drug Administration (FDA) to discuss a potential path forward for vilobelimab in PG.
- InflaRx does not expect to deploy significant resources towards future vilobelimab development in PG on its own, instead prioritizing izicopan development and considering vilobelimab development only in collaboration with a partner.
Dec 30, 2025, 12:57 PM
InflaRx Provides Update on Vilobelimab Phase 3 Data in Pyoderma Gangrenosum
IFRX
New Projects/Investments
Guidance Update
- InflaRx's Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint.
- Subsequent post-hoc analyses, however, suggested a positive trend in favor of vilobelimab, with signals indicating a potentially consistent treatment effect, including a significant treatment difference for percent change in target ulcer volume from Week 14 to Week 26 (e.g., -63.2% at Week 26, p=0.0122).
- InflaRx anticipates meeting with the FDA to determine a potential development path forward in PG, which the company expects would only be conducted in collaboration with a partner.
- The company will prioritize the development of izicopan (INF904) and does not expect to deploy significant resources towards future vilobelimab development in PG independently.
Dec 30, 2025, 12:30 PM
InflaRx Presents Positive Clinical Data for HS and CSU and Provides Financial Update
IFRX
New Projects/Investments
Guidance Update
- InflaRx presented positive data for its small oral C5aR inhibitor (904) in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). In HS, the 120 mg dose demonstrated the best performance across various metrics, including draining tunnels and patient-reported outcomes. For CSU, the 60 mg dose showed a clear and consistent effect on the Urticaria Activity Score.
- The company's drug (904) exhibits a much faster and higher exposure compared to Avacopan, achieving a 10x higher area under the curve (AUC) increase and reaching in the first week levels that Avacopan takes 13 weeks to achieve.
- InflaRx has completed required toxicology studies for indefinite dosing and plans a larger phase 2b study for HS, likely incorporating the 120 mg dose. Discussions with the FDA are underway, with HS as the initial priority.
- As of the end of Q3, InflaRx reported EUR 44.4 million (over $50 million) in cash, providing a financial runway into 2027.
Nov 11, 2025, 7:30 PM
InflaRx Announces Topline Phase 2a Data for INF904
IFRX
Product Launch
New Projects/Investments
- InflaRx (Nasdaq: IFRX) announced topline Phase 2a data for INF904 in Hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) on November 10, 2025.
- The Phase 2a trials for INF904 reported no signals of safety concern in both HS and CSU patients.
- For HS, INF904 demonstrated biologic-like efficacy within the first 4 weeks, with HiSCR and AN count reductions comparable to successful Phase 3 comparators, and an average ~65% reduction in pain (NRS30) at week 4.
- In CSU, INF904 effectively reduced UAS7 scores in both anti-IgE naive and experienced patients and demonstrated consistent improvement in angioedema up to week 4.
- INF904 also exhibited a superior pharmacokinetic/pharmacodynamic (PK/PD) profile and faster therapeutic exposure compared to reported avacopan data.
Nov 10, 2025, 1:00 PM
InflaRx Regains Nasdaq Minimum Bid Price Compliance
IFRX
Delisting/Listing Issues
- InflaRx N.V. has regained compliance with the Nasdaq Minimum Bid Price Requirement, as confirmed by Nasdaq on September 11, 2025.
- This compliance was achieved because the closing bid price of the company's ordinary shares was $1.00 or greater for 10 consecutive business days, from August 27, 2025, to September 10, 2025.
- InflaRx was initially notified of non-compliance on July 11, 2025, after its share price fell below $1.00 for 30 consecutive business days.
Sep 12, 2025, 8:05 PM
Quarterly earnings call transcripts for InflaRx.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more